Biocept continues to expand internationally by announcing that its Target Selector industry-leading blood-based test to detect EGFR mutations associated with lung cancer will now be accessible to patients in Mexico through a reference agreement with Quest Diagnostics Mexico.
Terms of the transaction were not disclosed. Biocept is a leading molecular diagnostics company that commercializes and develops liquid biopsy tests for cancer profiling and monitoring.
"Our high sensitivity test uses a simple blood sample to provide a cost-effective, viable option for patients with lung cancer who are often too sick for invasive tissue sampling," said Raaj Trivedi, Vice President of Commercial Operations at Biocept.
"Detecting the EGFR mutation can qualify patients for targeted therapy treatments that could lead to better outcomes."
"We are pleased to collaborate with Quest Diagnostics Mexico to make our test more accessible to the many patients in Mexico with lung cancer," added Mr. Trivedi.
"This collaboration also furthers our objective of actively expanding into geographies outside the U.S. and follows our recently announced distribution agreement for Israel."
"As an industry leader in the liquid biopsy space, we are providing comprehensive biomarker analysis in a rapid and cost-effective manner," said Michael Nall, President and CEO of Biocept.
"Our ability to expand internationally is a testament to the scalability of our platform as we deliver liquid biopsy testing to the medical community worldwide."